Adial Pharmaceuticals (ADIL) announced that it received notice from Nasdaq on February 23, 2026, that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Nasdaq determined that for the last 10 consecutive business days, from February 6 through February 20, 2026, the closing bid price of the Company’s common stock has been at $1.00 per share or greater.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADIL:
- Adial Pharmaceuticals highlights recent FDA policy, may reduce trial burden
- Adial Pharmaceuticals price target lowered to $8 from $37.50 at Maxim
- Adial Pharmaceuticals trading halted, news pending
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Why Is Adial Pharmaceuticals Stock (ADIL) Down Today?